Wednesday, February 28, 2024
BioCina Pty Ltd., a prominent global biologics Contract Development and Manufacturing Organization (CDMO), has forged a strategic partnership with NovaCina Pty Ltd., a well-known global fill-and-finish CDMO. Their collaboration aims to deliver integrated solutions for biologics developers, facilitating the seamless conversion of drug substances from BioCina's Adelaide, South Australia facility into finished drug products at NovaCina's Perth, Australia facility. This partnership marks a significant milestone in offering comprehensive biopharmaceutical manufacturing solutions worldwide.
BioCina specializes in providing high-quality and cost-effective CDMO services, including cell line development, process development, and cGMP drug substance manufacturing for microbial, pDNA, and mRNA modalities.
Through this collaboration, BioCina's clients gain access to NovaCina's extensive experience in clinical and commercial fill-and-finish operations, supported by regulatory approvals such as from the U.S. Food and Drug Administration (FDA). NovaCina offers a range of services covering development, manufacturing, packaging, labeling, and stability studies.
BioCina and a member of NovaCina's Board of Directors, expressed excitement about the partnership, emphasizing its potential to combine BioCina's global expertise with NovaCina's drug product services. Womack highlighted the partnership's commitment to delivering quality, regulatory compliance, and timely project execution.
NovaCina, shared Womack's enthusiasm, noting the partnership's ability to provide a seamless end-to-end solution. Mirsaidi emphasized NovaCina's dedication to maintaining high standards of quality and safety in the collaboration.
Source: prnewswire.com
